Clinical Trial Update: BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

BI-1607 in combination with Trastuzumab for HER2-positive advanced solid tumors (Phase 1/2) has been terminated. The study included HER2-positive breast cancer,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• BI-1607
• Trastuzumab (trastuzumab)

Snippet

Sponsor: BioInvent International AB | Conditions: HER2-positive Breast Cancer, HER2-positive Gastric Cancer | Phase 1, Phase 2 | Status: TERMINATED